Kiora Pharmaceuticals Inc (KPRX)

$4.1

-0.27

(-6.27%)

Market is closed - opens 7 PM, 19 Jul 2024

Performance

  • $4.09
    $4.24
    $4.10
    downward going graph

    0.24%

    Downside

    Day's Volatility :3.54%

    Upside

    3.3%

    downward going graph
  • $3.60
    $8.98
    $4.10
    downward going graph

    12.2%

    Downside

    52 Weeks Volatility :59.91%

    Upside

    54.34%

    downward going graph

Returns

PeriodKiora Pharmaceuticals IncIndex (Russel 2000)
3 Months
-4.7%
0.0%
6 Months
-9.99%
0.0%
1 Year
-24.06%
0.0%
3 Years
-99.33%
-18.2%

Highlights

Market Capitalization
12.5M
Book Value
$11.96
Earnings Per Share (EPS)
-11.79
Wall Street Target Price
33.0
Profit Margin
17.55%
Operating Margin TTM
82.56%
Return On Assets TTM
13.2%
Return On Equity TTM
12.46%
Revenue TTM
16.0M
Revenue Per Share TTM
13.26
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
-5.1M
EBITDA
6.3M
Diluted Eps TTM
-11.79
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.93
EPS Estimate Next Year
-2.7
EPS Estimate Current Quarter
-0.07
EPS Estimate Next Quarter
-0.08

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Kiora Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 704.88%

Current $4.10
Target $33.00

Technicals Summary

Sell

Neutral

Buy

Kiora Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Kiora Pharmaceuticals Inc
Kiora Pharmaceuticals Inc
1.97%
-9.99%
-24.06%
-99.33%
-99.33%
Moderna, Inc.
Moderna, Inc.
-6.91%
25.22%
1.18%
-60.44%
769.95%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
4.48%
16.73%
49.42%
85.5%
258.18%
Novo Nordisk A/s
Novo Nordisk A/s
-3.82%
25.91%
69.01%
206.62%
460.98%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.51%
12.79%
36.04%
145.12%
174.23%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Kiora Pharmaceuticals Inc
Kiora Pharmaceuticals Inc
0.76
NA
NA
0.93
0.12
0.13
NA
11.96
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
32.36
32.36
1.46
44.28
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
48.58
48.58
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.75
31.75
0.53
17.06
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Kiora Pharmaceuticals Inc
Kiora Pharmaceuticals Inc
Buy
$12.5M
-99.33%
0.76
17.55%
Moderna, Inc.
Moderna, Inc.
Buy
$48.0B
769.95%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$120.7B
258.18%
32.36
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$631.0B
460.98%
48.58
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.2B
174.23%
31.75
39.46%

Insights on Kiora Pharmaceuticals Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 69.0% return, outperforming this stock by 93.1%

Institutional Holdings

  • AIGH Capital Management, LLC

    8.76%
  • Rosalind Advisors, Inc.

    8.76%
  • Alyeska Investment Group, L.P.

    8.38%
  • Nantahala Capital Management, LLC

    7.24%
  • ADAR1 Capital Management LLC

    4.19%
  • Velan Capital Investment Management LP

    4.19%

Company Information

traded on nasdaq capital market, stock symbol eyeg, eyegate is a clinical-stage specialty pharmaceutical company that develops and commercializes products using two proprietary platform technologies for treating diseases and disorders of the eye. our most advanced platform is based on a crosslinked thiolated carboxymethyl hyaluronic acid (“cmha-s”), a modified form of the natural polymer hyaluronic acid (“ha”), which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface. our first cmha-s-based product candidate, the eyegate ocular bandage gel (“obg”), is a topically applied eye drop formulation that has completed its first-in-man clinical trial for the healing and lubricating of large epithelial defects following treatment after photorefractive keratectomy (“prk”) surgery. our initial product candidate from our second platform is egp-437, incorporates a reformulated topically active corticosteroid, dexamethasone

Organization
Kiora Pharmaceuticals Inc
Employees
12
CEO
Dr. Brian M. Strem Ph.D.
Industry
Miscellaneous

FAQs